Evidence map›Paper›PMID 38255803›Full record

ArticleInternational journal of molecular sciences2024

Developing Iron Nanochelating Agents: Preliminary Investigation of Effectiveness and Safety for Central Nervous System Applications.

Eleonora Ficiarà, Chiara Molinar, Silvia Gazzin, Sri Jayanti, Monica Argenziano, Lucia Nasi, Francesca Casoli, Franca Albertini, Shoeb Anwar Ansari, Andrea Marcantoni and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Eleonora FiciaràSchool of Pharmacy, Center for Neuroscience, University of Camerino, 62032 Camerino, Italy.
Chiara MolinarDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
Silvia GazzinFondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.ORCID 0000-0001-9403-3564
Sri JayantiFondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.ORCID 0000-0003-4554-504X
Monica ArgenzianoDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.ORCID 0000-0002-8485-7460
Lucia NasiInstitute of Materials for Electronics and Magnetism (IMEM) CNR, Parco Area delle Scienze 37/A, 43124 Parma, Italy.ORCID 0000-0002-1663-1558
Francesca CasoliInstitute of Materials for Electronics and Magnetism (IMEM) CNR, Parco Area delle Scienze 37/A, 43124 Parma, Italy.ORCID 0000-0002-4323-0362
Franca AlbertiniInstitute of Materials for Electronics and Magnetism (IMEM) CNR, Parco Area delle Scienze 37/A, 43124 Parma, Italy.ORCID 0000-0002-7210-0735
Shoeb Anwar AnsariDepartment of Neurosciences, University of Turin, 10124 Turin, Italy.
Andrea MarcantoniDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.ORCID 0000-0001-5825-7827
Giulia TomagraDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.ORCID 0000-0003-2090-3402
Valentina CarabelliDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
Caterina GuiotDepartment of Neurosciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0001-8529-1625
Federico D'AgataDepartment of Neurosciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0001-9432-0248
Roberta CavalliDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
University of Turin · ITInstitute of Materials for Electronics and Magnetism · ITFondazione Italiana Fegato · ITUniversità di Camerino · IT

Funding

San Paolo-UNITO S1921_EX-POST_21_01University of Turin C.G. F.D.A. RiLo22, C.G. RiLo23
6 · The paper itself

Abstract

Excessive iron levels are believed to contribute to the development of neurodegenerative disorders by promoting oxidative stress and harmful protein clustering. Novel chelation treatments that can effectively remove excess iron while minimizing negative effects on the nervous system are being explored. This study focuses on the creation and evaluation of innovative nanobubble (NB) formulations, shelled with various polymers such as glycol-chitosan (GC) and glycol-chitosan conjugated with deferoxamine (DFO), to enhance their ability to bind iron. Various methods were used to evaluate their physical and chemical properties, chelation capacity in diverse iron solutions and impact on reactive oxygen species (ROS). Notably, the GC-DFO NBs demonstrated the ability to decrease amyloid-β protein misfolding caused by iron. To assess potential toxicity, in vitro cytotoxicity testing was conducted using organotypic brain cultures from the substantia nigra, revealing no adverse effects at appropriate concentrations. Additionally, the impact of NBs on spontaneous electrical signaling in hippocampal neurons was examined. Our findings suggest a novel nanochelation approach utilizing DFO-conjugated NBs for the removal of excess iron in cerebral regions, potentially preventing neurotoxic effects.

Indexed as

IronIron OverloadAmyloid beta-PeptidesBrainCentral Nervous SystemHumansAmyloid beta-PeptidesIronchelationDFOironnanobubblesneurodegeneration

Identifiers

PMID38255803
PMCPMC10815234
OpenAlexW4390616848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.